Switzerland
· Delayed Price · Currency is CHF Spexis AG Company Description
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer.
Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs.
Spexis AG is headquartered in Allschwil, Switzerland.
| Country | Switzerland |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Jeffrey Wager |
Contact Details
Address: Hegenheimermattweg 125 Allschwil, 4123 Switzerland | |
| Phone | 41 61 567 16 00 |
| Website | spexisbio.com |
Stock Details
| Ticker Symbol | SPEX |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0106213793 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey David Wager | President, Chief Executive Officer, Treasurer, Chairman and Secretary |
| Dr. Daniel L. Hartman FCCP, M.D. | Co-Founder and Director |
| Dr. James J. Collins Ph.D. | Founder |
| Martin Jakobovic | Interim Chief Financial Officer |
| Muriel Fleming | Head of Human Resources |
| Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical and Development Officer |
| Dr. Goncalo Bernardes | Acting Head of Chemical Biology |
| Gokhan Batur | Executive Officer |